MindWalk Holdings Corp.

MindWalk Holdings Corp. announced it will report its financial results for the first quarter of fiscal year 2027 on September 14, 2026. The company will host a conference call and webcast on the same day at 5:00 p.m. Eastern Time to discuss the results, which will be issued in a press release beforehand. The event will include a management presentation and a Q&A session, with replays available on the company's investor relations website.

MindWalk Holdings Corp. publicly demonstrated ReefIQ™, its biological context layer for AI drug discovery, at AMD's Advancing AI 2026 event. ReefIQ™ aims to reconnect fragmented biological data, enabling AI models to reason over a governed, queryable context, and runs on AMD Instinct™ compute. This demonstration marks the first public showing of the platform, which was introduced in June 2026, and is designed to enhance the trustworthiness of AI reasoning in drug discovery.

MindWalk Holdings Corp. reported strong fiscal year 2026 results, with revenue increasing 46% to 15.6 million as the company completed its strategic pivot to Bio-Native AI infrastructure. Gross margin expanded to 59%, and the net loss narrowed by more than half, reflecting a sharpened focus on BioIntelligence. The company also divested a non-core business, regained Nasdaq compliance, and launched its ReefIQ™ platform.

MindWalk Holdings Corp. announced it will report its financial results for the fourth quarter and full fiscal year 2026 on Wednesday, July 22, 2026. The company will also host a conference call and webcast on the same day at 5:00 p.m. Eastern Time to discuss the results and recent business highlights. Financial results will be issued in a press release prior to the call.

MindWalk Holdings Corp. announced the filing of European patent application No. EP26187897.9, which is directed to high-dimensional data structures for biological subsequences and property inference. This patent aims to protect the enriched biological representation architecture that underpins the company's HYFT® Technology, ReefIQ™ biological context layer, and LensAI™ reasoning workflows. The company believes this model-agnostic data layer provides a durable advantage in life sciences by enabling AI models to retrieve, compare, and reason over biology with traceable context, supporting the growing AI drug discovery market.

MindWalk Holdings Corp. announced that its President and CEO, Dr. Jennifer Bath, will participate in a virtual panel at Jones AI Day on June 15, 2026. The panel, titled "Partnering to Power the New Era of Drug Discovery," will explore how advanced computing and AI can overcome challenges in drug discovery. Dr. Bath will discuss MindWalk's bio-native AI approach, emphasizing its HYFT® technology and ReefIQ™ biological context layer, which features 660 million biological patterns and 25 billion relationships, and the LensAI™ platform, which is already in contracted arrangements with customers.

MindWalk Holdings Corp. announced the launch of ReefIQ™, a new biological context layer designed for AI drug discovery and biologics development. ReefIQ™ leverages MindWalk's proprietary HYFT® technology to transform fragmented biological data into a governed, queryable context for AI reasoning workflows. This new layer aims to preserve valuable insights from all discovery programs, enriching future efforts and integrating with the company's existing LensAI™ platform, which is already in use with life-sciences customers.

MindWalk Holdings Corp. reported preclinical dengue data that supports a computational prediction generated by its HYFT® platform. The platform identified a candidate pan-serotype structural target on the dengue virus, and subsequent animal immunization with immunogens designed on this target generated antibodies that cross-reacted with antigens of all four dengue serotypes. This clear and consistent trend was reproduced across two independent campaigns, providing MindWalk's first public evidence that its AI-driven platform can connect computational predictions to measurable biological outcomes. Future studies will assess the antibodies' functional profile, including neutralization and interaction with ADE pathways.

MindWalk Holdings Corp. announced the launch of its Pandemic Response Platform, utilizing its proprietary HYFT® biological pattern system and LensAI™ platform. This platform is designed for outbreak preparedness, rapid countermeasure design, and pan-strain antigen and antibody generation against rapidly mutating RNA viruses. It targets the structural constraints viruses must preserve, bypassing the limitations of surface-focused countermeasures. The platform is currently deployed on the company's pan-serotype Dengue and universal Influenza programs.